e8vk
Table of Contents

 
 
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): September 22, 2006
EPIX PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
         
Delaware   000-21863   04-3030815
 
(State or Other
Jurisdiction of
Incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)
     
4 Maguire Road, Lexington, Massachusetts   02421
 
(Address of Principal Executive Offices)   (Zip Code)
Registrant’s telephone number, including area code (781) 372-3260
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
  o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
  o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
  o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
  o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 


TABLE OF CONTENTS

Item 7.01 Regulation FD Disclosure
Item 9.01 Financial Statements and Exhibits
SIGNATURES
EXHIBIT INDEX
EX-99.1 PRX-00023 presentation dated September 22, 2006


Table of Contents

Item 7.01 Regulation FD Disclosure.
     On September 22, 2006, EPIX Pharmaceuticals, Inc. (the “Company”) participated in a conference call at 8:30 a.m. to discuss the results of its Phase III clinical trial of PRX-00023 for generalized anxiety order and depression. A copy of the presentation used in the conference call is being furnished as Exhibit 99.1 to this Report on Form 8-K.
     This Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as explicitly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d)   Exhibits:
99.1   PRX-00023 presentation dated September 22, 2006, furnished herewith.

- 2 -


Table of Contents

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
                 
    EPIX PHARMACEUTICALS, INC.    
 
               
Dated: September 22, 2006   By:   /s/ Kimberlee Drapkin    
             
 
      Name:   Kimberlee Drapkin    
 
      Title:   Chief Financial Officer    

- 3 -


Table of Contents

EXHIBIT INDEX
     
Exhibit Number   Description
 
   
99.1
  PRX-00023 presentation dated September 22, 2006, furnished herewith.

- 4 -